Last reviewed · How we verify
conventional oral iron
At a glance
| Generic name | conventional oral iron |
|---|---|
| Sponsor | Medeni Şermet |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Liposomal vs Conventional Oral Iron After Sleeve Gastrectomy (NA)
- Evaluating the Effect of N-Acetyl Cysteine and Alpha Lipoic Acid in Patients With Beta Thalassemia (PHASE3)
- Roxadustat's Effect on Heart, Nutrition, and Inflammation in Hemodialysis Patients (PHASE1, PHASE2)
- Roxadustat for Bone and Neuropsychiatric Aspects in Hemodialysis Patients (PHASE1, PHASE2)
- Effect of the Combined Programme on Perioperative Anaemia（CPPA） (NA)
- Patient Blood Mangement (PBM) Using IV Iron in Patients With Gynecologic Cancer (NA)
- Enhanced Recovery Protocol in Urogynecologic Surgery (NA)
- FLIPS: Ferfer Liposomal Iron Performance Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- conventional oral iron CI brief — competitive landscape report
- conventional oral iron updates RSS · CI watch RSS
- Medeni Şermet portfolio CI